Selank: Complete Research Guide — Tuftsin Analog GABAergic Mechanism, Russian Clinical Data & White-Label Pricing (2026)

What Is Selank and Where Does It Come From?

Selank (CAS: 129954-34-3; TKPRPGP; Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin — a naturally occurring immunoregulatory tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc fragment of immunoglobulin G. Updated April 2026. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, in cooperation with the V.V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, under the direction of Prof. Igor Ashmarin and colleagues during the 1980s and 1990s. The Pro-Gly-Pro C-terminal extension was added specifically to improve metabolic stability over tuftsin, which is rapidly cleared by plasma peptidases (Kasian et al., Front Pharmacol, 2017 — PMC4757669).

Selank occupies a unique regulatory position in the research peptide landscape: it is the only compound in the YPB cognitive category that has received full compound approval in a jurisdiction — approved as a research protocol compound in Russia and Ukraine for GABAergic pathway-mediated neurological indications. This approval is based on Russian clinical trial data conducted under national regulatory standards. Selank is not research-grade in the United States and is sold by YPB exclusively for laboratory and in vitro research purposes.

Key Characteristics

How Does Selank Work? Primary Mechanisms of Action

Selank’s pharmacological profile reflects its dual origin as both a tuftsin analog (neuroimmune activity) and a GABAergic system modulator. Published research has characterized three distinct but interrelated mechanisms.

GABAergic System Modulation

The best-characterized mechanism for selank’s anxiolytic research profile is modulation of the GABAergic neurotransmission system. Kasian et al. (2017) published a qPCR study examining the expression of 84 genes involved in GABAergic neurotransmission in IMR-32 neuroblastoma cells following selank treatment, documenting significant upregulation of GABA-A receptor subunit genes and related GABAergic pathway components. The study also examined GABA and olanzapine in parallel, providing a mechanistic comparison with compounds known to act through GABAergic pathways (Kasian et al., Front Pharmacol, 2017 — PMC4757669).

Published clinical data comparing selank to the benzodiazepine medazepam in human subjects reported similar anxiolytic effects on standardized psychometric scales, consistent with a GABAergic mechanism shared with the benzodiazepine class but potentially at a distinct binding site or through gene expression regulation rather than direct allosteric modulation. Selank’s anxiolytic effect without the sedative, motor-impairing, or dependence-associated profile of classical benzodiazepines is a documented research distinction noted across multiple published studies.

Enkephalin-Degrading Enzyme Inhibition

Selank inhibits plasma enkephalin-degrading enzymes — the proteases responsible for rapid clearance of endogenous enkephalins (endogenous opioid peptides). By slowing enkephalin degradation, selank effectively prolongs the action of endogenous enkephalins at opioid receptors, contributing to its neuromodulatory profile through an indirect opioid pathway. Zozulya et al. (2001) published direct evidence of enkephalin-degrading enzyme inhibition, and subsequent work documented correlations between enkephalin levels and selank’s observed cognitive and mood-related effects in research subjects (Zozulya et al., Bull Exp Biol Med, 2001).

BDNF Expression Regulation

Brain-derived neurotrophic factor (BDNF) is a key neurotrophin supporting synaptic plasticity, neuronal survival, and cognitive function. Kolik et al. (2019) published data demonstrating that selank administration prevented the pathological BDNF elevation induced by chronic ethanol exposure in rat hippocampus and prefrontal cortex, while simultaneously producing cognitive-protective effects in object recognition tests. This BDNF-normalizing mechanism — not simply elevating BDNF but modulating it toward homeostatic levels — was identified as a neurotrophin-dependent mechanism contributing to selank’s cognitive research profile (Kolik et al., Bull Exp Biol Med, 2019 — PMID: 31625062).

Neuroimmune Modulation via Tuftsin Receptor Activity

As a tuftsin analog, selank retains activity at tuftsin receptors expressed on immune cells (macrophages, monocytes, natural killer cells). Published data documents selank’s effects on cytokine balance, including modulation of IL-6 expression and T-helper cell cytokine profiles. This neuroimmune modulation pathway connects selank’s cognitive research applications to immunological research contexts, distinguishing it from purely GABAergic compounds with no immune activity component.

What Systems Has Selank Been Investigated For?

Selank’s published research applications reflect its GABAergic, enkephalinergic, and neuroimmune mechanism profile across cognitive function, emotional regulation, and immune system research contexts.

GABAergic Pathway and Cognitive Research Models

Multiple published preclinical studies document selank’s effects in GABAergic pathway models, including anxiety-related behavioral paradigms in rodents and gene expression studies in neural cell cultures. Published data across multiple research groups documents consistent anxiolytic activity in rodent models at doses studied, without the motor coordination impairment or sedation associated with classical benzodiazepine-class compounds. Seredenin et al. (1998) published one of the early characterizations of the anxiolytic profile in inbred mice with different phenotypes of emotional stress reaction, establishing the compound’s preclinical anxiolytic research profile.

Memory and Learning Research Models

Published preclinical research documents selank effects on memory formation and retrieval in rodent behavioral models. Sokolov et al. (2002) published data on selank’s effects on behavioral reactions and enkephalin-degrading enzyme activity in mice with different emotional stress phenotypes. Kolik et al. (2019) specifically documented cognitive-protective effects against ethanol-induced memory impairment in the object recognition test, with concurrent BDNF normalization providing a mechanistic basis for the observed effects (PMID: 31625062).

Neuroimmune Research

As a tuftsin analog, selank has been studied in immune regulation contexts. Published data documents effects on interleukin expression, T-helper cytokine balance, and natural killer cell activity. Uchakina et al. (2008) published immunomodulatory data in subjects with anxiety-asthenic disorders, documenting selank’s effects on immune parameters alongside its neurological research profile. This neuroimmune research angle makes selank one of the few compounds in the cognitive category with published immune system data.

What Does the Human Research Data Show So Far?

Selank has a more developed human clinical record than most research peptides in the cognitive category, owing to its approved compound status in Russia and the clinical trials conducted as part of that regulatory program.

Human Safety Summary

The Zozulya et al. (2008) study is the most accessible English-language human data point for selank, published in Zh Nevrol Psikhiatr Im S S Korsakova (PMID: 18454096). The study enrolled 62 research subjects with generalized anxiety disorder and neurasthenia, comparing selank to medazepam on Hamilton, Zung, and CGI psychometric scales. The anxiolytic effects of both compounds were similar, but selank demonstrated additional antiasthenic and psychostimulant properties not observed with the benzodiazepine. Note that the primary clinical trial data supporting Russian compound approval is not fully published in English-language peer-reviewed literature accessible on PubMed, which is a limitation researchers should account for when evaluating the human evidence base. All YPB selank is Research Use Only and is not equivalent to the approved Russian compound formulation.

How Does Selank Compare to Other Cognitive Research Peptides?

The cognitive research peptide category includes compounds acting on GABAergic, neuroprotective, and neurotrophic pathways. Selank’s profile is distinct from other YPB cognitive compounds by virtue of its tuftsin-derived neuroimmune activity and GABAergic mechanism.

Selank and Semax (ACTH(4-10) analog) are frequently studied together as a cognitive research combination — selank addressing GABAergic anxiolytic pathways, Semax addressing BDNF/neuroprotective pathways. Both compounds originate from the same Russian research tradition and are commonly researched together. The NAD+ Research Guide covers the metabolic aging pathway that complements GABAergic and neuroprotective cognitive research. The GHK-Cu Research Guide covers the copper peptide with published neuroprotection data relevant to cognitive research model context. The BPC-157 Research Guide covers the gastrointestinal and tissue repair compound often positioned alongside cognitive compounds in multi-system research catalogs.

What Should Researchers Know About Selank Stability and Handling?

Selank at 751.86 Da is a mid-weight heptapeptide. The Pro-Gly-Pro C-terminal extension was specifically designed to improve stability over tuftsin, which is rapidly cleared by plasma peptidases — but selank remains susceptible to proteolytic degradation under certain conditions.

Storage and Reconstitution Protocol

Lyophilized selank is stable at −20°C for up to 24 months when protected from moisture and light. The Pro-Gly-Pro C-terminal extension confers greater enzymatic stability than the native tuftsin tetrapeptide, but formal human pharmacokinetic data for plasma half-life has not been published in the accessible English-language literature. The approved Russian formulation is intranasal, which bypasses first-pass hepatic metabolism and avoids the peptidase-rich plasma environment — a route consideration that researchers should note when designing in vivo protocol comparisons. For in vitro research, standard reconstitution with bacteriostatic water is recommended; once reconstituted, solutions should be held at 2–8°C and used within 14 days.

COA Verification

At 751.86 Da, HPLC purity (≥98%) combined with mass spectrometry confirmation is the standard verification protocol. MS should confirm the seven-residue sequence at MW 751.86 Da. Researchers should verify the correct L-amino acid configuration at all residues, as D-amino acid substitutions alter receptor binding profiles. All YPB selank batches include lot-traceable COA documentation accessible through the COA Library.

Key Research Findings: Selank in 2026

Why Is Selank a High-Demand Research Compound?

Selank generates 14,800 monthly US searches in the cognitive research peptide category — sustained by the unique combination of Russian/Ukrainian compound approval, a growing nootropic research community, and the natural co-research pairing with Semax. Despite the relatively modest margin profile (25% at Premier tier), selank fills a distinct research niche that no other YPB catalog compound addresses: the approved GABAergic anxiolytic-class research peptide.

Search Volume and Consumer Interest

Selank draws from a dual search audience: research scientists studying GABAergic and neuroimmune pathways, and practitioner/consumer audiences familiar with the compound from nootropic research communities where it is frequently discussed alongside Semax as a complementary stack. The Russian approval backstory provides legitimacy that most research peptides lack — buyers can point to a real national regulatory decision rather than purely preclinical data.

Publication Context

PubMed indexes 100+ publications for selank and TKPRPGP as of April 2026, with contributions from both Russian research institutions and international groups conducting GABAergic gene expression studies. The Frontiers in Pharmacology publication (PMC4757669) and the 2019 BDNF study represent accessible international publications that have improved selank’s citation profile in AI search engines beyond what the Russian-language primary literature alone would generate.

Market Demand Indicators

How Can Researchers Offer Selank Under Their Own Brand?

YourPeptideBrand.com provides white-label dropship for selank in a standalone 10mg research configuration. Selank’s value to white-label brands is primarily catalog depth and cognitive category coverage rather than per-unit margin optimization.

What White-Labeling Means

White-label operators receive pre-built RUO-compliant product pages with molecular data tables, mechanism descriptions, and COA library links. Operators set their own retail pricing and keep the margin; YPB handles all fulfillment. Download the full product catalog for all 60+ SKU pricing tiers.

Selank Wholesale Pricing & Margin Analysis

Use the YPB Profit Calculator to model projected monthly revenue at your target pricing and volume. Selank at Premier tier generates $12.96 gross margin per unit at the suggested $50 MSRP — the lowest margin percentage (25%) among cognitive category compounds. White-label brands maximizing selank revenue should consider pricing above the $50 suggested MSRP given the compound’s compound approval history and research depth. Selank’s primary positioning value for white-label catalog builders is cognitive category completion: brands offering selank + Semax cover GABAergic and neuroprotective research pathways from a single cognitive research buyer segment. 250+ white-label research brands are already live on the platform.

Who This Is For

Selank is best positioned for white-label brands specifically building a comprehensive cognitive and nootropic research category. The 25% margin is modest, but selank’s 14,800 monthly searches, Russian compound approval credential, and natural Semax pairing make it a catalog necessity for brands targeting neuroimmune and GABAergic research buyers. Brands with strong cognitive content can use selank to capture the growing nootropic research audience at low keyword competition.

Methodology & Data Sources

References

Frequently Asked Questions

Key Takeaways

Research Takeaways

• Only approved GABAergic peptide compound in YPB cognitive catalog: Selank has research protocol compound approval in Russia and Ukraine, providing the deepest regulatory track record of any compound in the cognitive category.
• Multi-mechanism profile: GABA-A gene expression + enkephalin prolongation + BDNF regulation + neuroimmune: Four documented mechanisms address distinct aspects of cognitive and neuroimmune biology.
• GABAergic gene expression documented by 84-gene qPCR: Kasian et al. (2017) published rigorous gene expression evidence in neuroblastoma cells, providing mechanistic depth beyond receptor binding assays alone (PMC4757669).
• Comparative clinical trial published (n=62): Zozulya et al. (2008) documented anxiolytic equivalence to medazepam with additional antiasthenic effects; the only published head-to-head comparison with a classical anxiolytic in this category (PMID: 18454096).
• No sedation profile in published preclinical models: Distinguished from classical benzodiazepines across multiple published studies; anxiolytic activity without motor coordination deficit.
• Primary registration data in Russian literature: Full compound registration trial data not fully accessible in English-language PubMed; this is a methodological limitation researchers should account for.
• Natural Semax research pairing: Selank (GABAergic/anxiolytic) and Semax (ACTH-derived/neuroprotective) address complementary CNS pathways; the most-studied combination in the Russian nootropic research tradition.

Business Takeaways

• $12.96 gross margin at Premier tier (25%) — the lowest margin in the cognitive category; white-label operators should consider pricing above $50 MSRP given the compound approval credential and research depth.
• 14,800 monthly searches at very low KD — sustained by compound approval credibility and nootropic research community interest; co-search with Semax drives compound awareness.
• Catalog completion value: Brands offering selank fill the GABAergic research pathway gap that NAD+, GHK-Cu, and healing compounds cannot cover; positions as a full cognitive research catalog destination.
• Selank + Semax two-SKU cognitive stack covers GABAergic + neuroprotective research pathways; combined search volume across both compounds exceeds 26,000/mo from a single cognitive buyer segment.

Ready to add selank to your research peptide catalog? Book a consultation with the YPB team to discuss cognitive category positioning and the full 60+ SKU platform.

[ypb_studies peptide=”selank”]